Deals Of The Week: GSK/HGSI, Daiichi Sankyo/Coherus
GSK/Human Genome story takes a sharp turn, but does the big pharma’s hostile bid expose greater interest in cardiovascular drug darapladib than it is admitting?
You may also be interested in...
Migraine Snapshot: Despite Significant Generic Presence, MAP, Allergan, Others See Big Market Potential
After a 20-year hiatus, the market for acute and chronic migraine is set to expand with the introduction of Allergan’s Botox and of novel formulations of triptans and alternative therapies.
Human Genome Sciences says the long-term blockbuster opportunity in Benlysta and the potential of its pipeline products are under-valued by GlaxoSmithKline’s takeover offer. Management at GSK, however, plays down any talk of increasing its bid.
GlaxoSmithKline swoops in to acquire its research partner Human Genome Sciences – made vulnerable by the weak launch of Benlysta – for $13 per share in cash, or about $2.6 billion.